Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

We recently compiled a list of the 8 Most Undervalued Value Stocks To Buy According To Analysts. In this article, we are ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance ...

Edward’s Syndrome Treatment MarketThe global Edward’s syndrome treatment market is set for significant growth, with a projected market value of USD 7.98 Billion by 2033, according to a newly released ...

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...